Add-on activity
This activity features patient case reviews.
Program Description
Non−small cell lung cancer (NSCLC) is not only one of the most commonly diagnosed malignancies, but also presents with a variety of driver mutations, including epidermal growth factor receptor, ALK, ROS1, and KRAS, among others, for which specific therapy should be targeted. The ROS1 and KRAS mutations have been associated with limited response to existing targeted therapies, with patients eventually developing resistance, necessitating research into more potent and mutation-specific treatment options. This webinar will review updated clinical data for approved and investigational targeted tyrosine kinase inhibitor therapies specific to patients with ROS1-rearranged and KRAS-mutant NSCLC, respectively, as well as resulting updates in clinical practice guidelines. Patient case reviews incorporated within the activity will present opportunities for oncology pharmacists to identify candidates for treatment with these novel therapies and share key counseling points regarding dosing, administration, and adherence. Strategies for pharmacists to identify potential drug-drug interactions and mitigate toxicities associated with targeted tyrosine kinase inhibitor therapies in ROS1-rearranged and KRAS-mutant NSCLC will also be examined.
Target audience: Health-system and oncology pharmacists
Type of activity: Application
Release date: December 15, 2022
Expiration date: February 15, 2023
Time to complete activity: 1 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the epidemiologic importance of KRAS-mutant and ROS1-rearranged non−small cell lung cancer
- Illustrate the pharmacology of tyrosine kinase inhibitors for the treatment of KRAS-mutant and ROS1-rearranged non−small cell lung cancer
- Classify the role of the pharmacist in the promotion of adherence and management of toxicities associated with oral tyrosine kinase inhibitors
Stefanie L. Houseknecht, PharmD, BCOP
Clinical Pharmacy Specialist
Thoracic Oncology
The Johns Hopkins Hospital and Bayview Medical Center
Baltimore, Maryland
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-509-L01-P. The activity is available for CE credit through February 15, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Stefanie L. Houseknecht, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:
Consultant: Aptar Pharma
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Rose Buszka, PharmD, BCPS, CHCP; Abigail Dill; Susan Pordon; Chloe Taccetta; and Brianna Winters have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms